Bio-Techne: Flat Revenue, Better Margins and APAC Momentum

Transcript intelligence

What changed

Compared with the prior quarter, the analysis shifted from a 1% organic revenue decline and a 200–400 basis-point cell-therapy headwind to flat Q2 revenue, 31.1% operating margin, continued China growth and a mid-single-digit underlying growth outlook for the rest of FY26.

Guidance delta

Guidance sentiment remained maintained; management expects mid-single-digit underlying organic growth for the remainder of FY26 once temporary customer timing impacts are excluded.

Key takeaways

• Q2 revenue was flat year over year, while operating margin expanded to 31.1%.
• Management said underlying growth should be mid-single-digit for the remainder of FY26 excluding temporary customer impacts.
• China posted a third consecutive quarter of growth, and APAC growth approached 20%.
• Growth verticals reached 47% of revenue, supported by cell therapy, instruments, spatial biology and diagnostics.

Management priorities

• Complete the full Wilson Wolf acquisition by the end of 2027.
• Roll out ultrasensitive Ella assays for neurological biomarkers.
• Enhance the LEO platform with fluorescence detection for multiplexing.
• Expand organoid products, including synthetic hydrogel offerings.
• Pursue margin expansion through mix improvements and investment in growth verticals.